Vaccines-2013 - OMICS Group

Recommendations

Info

Yongqun “Oliver” He et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAApplications of the vaccine ontology (vo) in vaccine data integration and computer-assistedautomated reasoningYongqun “Oliver” He, Yu Lin and Zuoshuang XiangUniversity of Michigan Medical School, USAbiomedical ontology is a set of terms and relations that represent entities and relations between these entities in a specificA biomedical domain. Biomedical ontologies support biomedical data exchange, integration, and advanced data analysis.Developed using the Web Ontology Language (OWL), the Vaccine Ontology (VO) is a community-based biomedical ontologyin the domain of vaccine and vaccination. Currently VO includes over 3,000 vaccine-associated terms. VO represents all licensedhuman vaccines in the USA and Canada, all licensed veterinary vaccines in the USA, and over 1,000 vaccines under clinicaltrials and research. VO also includes those microbial genes and proteins that have been used for vaccine development. Therelations between these genes and proteins and various vaccines are logically defined. VO integrates vaccine data stored in thecomprehensive VIOLIN vaccine database and analysis system (http://www.violinet.org). VIOLIN also uses VO to integratedifferent types of VIOLIN data curation, storage, and analysis. Through the linkage between VO and existing ontologies, vaccinedata can seamlessly be analyzed. For example, the gene and protein data stored in VO are linked to NCBI taxonomy, NCBIRefSeq and Gene databases, and MeSH/PubMed systems. These linkages allow advanced analysis of vaccine-associated genesand proteins. Currently VO and RDF-based Linked Open Vaccine Data (LOVD) system is under development. LOVD andSPARQL-based Semantic Web technology will allow the integration and query of various vaccine data from different resources.Case studies will be introduced to demonstrate the power of the VO in advanced data integration and analysis.BiographyYongqun He “Oliver” is an Associate Professor in the University of Michigan Medical School. He is experienced in both vaccinology and computersciences. His primary interests are host-vaccine interaction mechanism analysis, vaccine development, computational vaccinology, andbioinformatics. His group has developed many vaccine informatics programs including the VIOLIN vaccine database and analysis system andVaxign vaccine design program. He initiated and leads the development of the community-based Vaccine Ontology (VO). He has published over 50peer-reviewed papers and is an editorial board member of several journals.yongqunh@med.umich.eduJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 50
Takashi Kei Kishimoto, J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USARational design of synthetic vaccine particles (SVP) for therapeutic treatment of chronic diseasesTakashi Kei KishimotoSelecta Biosciences, USAVaccines for the prophylaxis of infectious diseases have been one of the most effective interventions for improving humanhealth. Recent advances in immunology and vaccine technology have opened the door to novel vaccine-based therapiesfor the therapeutic treatment of chronic diseases. We have developed a flexible and modular Synthetic Vaccine Particle (SVP)technology that enables the rational design of both stimulatory vaccines and tolerogenic immune therapies. Our targeted SVPs(tSVP) have been designed and optimized to promote efficient cross-presentation of antigen and stimulate robust cellularimmunity for the treatment of cancer and chronic infections, while our tolerogenic targeted SVPs (t 2 SVP) are designed to induceimmune tolerance for the treatment of autoimmune diseases, allergies, and immunogenicity of biological therapies. We willdescribe the general design principles of these synthetic, self-assembling nanoparticles and provide examples for use in variousdisease settings.BiographyTakashi Kei Kishimoto is the Chief Scientifi c Offi cer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on anovel self-assembling nanoparticle technology. Prior to joining Selecta, he was Vice President of Research at Momenta Pharmaceuticals wherehe led a multidisciplinary team in advancing both novel and complex generic products. Previously he held leadership positions at MillenniumPharmaceuticals and Boehringer Ingelheim. He has published over 50 peer-reviewed articles, including articles in Nature, Science, Cell, and theNew England Journal of Medicine. He received his doctoral degree in Immunology from Harvard University and his post-doctoral training at StanfordUniversity.KKishimoto@selectabio.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 51
Page 1 and 2: 111 th OMICS Group ConferenceJuly 2
Page 3 and 4: Medical SciencesISSNAddiction Resea
Page 5 and 6: Impact Factors (IF) and Index Coper
Page 7 and 8: 111 th OMICS Group Conference3 rd I
Page 9 and 10: Journal of Clinical & Cellular Immu
Page 15 and 16: Clinical Microbiology-2013OMICS Gro
Page 17 and 18: Immunology Summit-2013OMICS Group i
Page 19 and 20: Probiotics-2013OMICS Group is organ
Page 21 and 22: Virology-2013OMICS Group is organiz
Page 25 and 26: Because of heightened awareness of
Page 33 and 34: Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36: Nikolai Petrovsky, J Vaccines Vacci
Page 39 and 40: Robert E. Sievers et al., J Vaccine
Page 41 and 42: Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44: Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46: Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48: Diane Longo et al., J Vaccines Vacc
Page 49: Track 33: Novel Approaches in Desig
Page 53 and 54: Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56: A. Bennett Jenson et al., J Vaccine
Page 57 and 58: Milan Raska et al., J Vaccines Vacc
Page 59 and 60: Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62: Track 44: Vaccines against Infectio
Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102:
Zafer Kurugol et al., J Vaccines Va
Page 103 and 104:
Ates Kara et al., J Vaccines Vaccin
Page 105 and 106:
Yurong Tan et al., J Vaccines Vacci
Page 107 and 108:
Deryabin P.N. et al., J Vaccines Va
Page 109 and 110:
Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112:
Byung Chul Kim et al., J Vaccines V
Page 113 and 114:
STS. Chitradevi et al., J Vaccines
Page 115 and 116:
Yan Liang et al., J Vaccines Vaccin
Page 117 and 118:
111 th OMICS Group Conference3 rd I
Page 119 and 120:
Afshineh Latifynia et al., J Vaccin
Page 121 and 122:
Hemanta Koley et al., J Vaccines Va
Page 123 and 124:
Aleksandar Masic et al., J Vaccines
Page 125 and 126:
Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128:
Oladipo Aina et al., J Vaccines Vac
Page 129 and 130:
Aiswariya Chidambaram, J Vaccines V
Page 131 and 132:
Birhanu Hurisa et al., J Vaccines V
Page 133 and 134:
Ghaffarifar F et al., J Vaccines Va
Page 135 and 136:
Mathan Periasamy et al., J Vaccines
Page 137 and 138:
Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140:
Samuel Teshome, J Vaccines Vaccin 2
Page 141 and 142:
111 th OMICS Group Conference3 rd I
Page 143 and 144:
Birhanu Hurisa et al., J Vaccines V
Page 145 and 146:
Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148:
Belachew Etana et al., J Vaccines V
Page 149 and 150:
Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152:
Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154:
Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156:
Sandeepkumar R. Chauhan et al., J V
Page 157 and 158:
Veronica Rainone et al., J Vaccines
Page 159 and 160:
Page 159
Page 161 and 162:
Previous111 th OMICS Group Conferen
Page 163 and 164:
PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

Create successful ePaper yourself

Delete template?

Save as template?